Carisma Therapeutics
Stock Forecast, Prediction & Price Target
Carisma Therapeutics Financial Estimates
Carisma Therapeutics Revenue Estimates
Carisma Therapeutics EBITDA Estimates
Carisma Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $26.54M N/A | $9.83M -62.95% | $14.91M 51.70% | Avg: $7.19M Low: $6.84M High: $7.70M avg. -51.75% | Avg: $27.21M Low: $25.86M High: $29.13M avg. 278.16% | Avg: $33.25M Low: $31.60M High: $35.60M avg. 22.18% | Avg: $12.20M Low: $11.59M High: $13.06M avg. -63.30% |
Net Income
% change YoY
| $-40.77M N/A | $-61.22M -50.15% | $-86.87M -41.89% | Avg: $-73.00M Low: $-69.39M High: $-22.79M avg. 15.96% | Avg: $-84.30M Low: $-70.06M High: $-21.79M avg. -15.47% | Avg: $-70.40M Low: $-76.85M High: $-65.86M avg. 16.49% | Avg: $-64.03M Low: $-69.90M High: $-59.90M avg. 9.04% |
EBITDA
% change YoY
| $-40.11M N/A | $-50.07M -24.83% | $-85.89M -71.54% | Avg: $-4.31M Low: $-4.62M High: $-4.10M avg. 94.97% | Avg: $-16.33M Low: $-17.48M High: $-15.52M avg. -278.16% | Avg: $-19.95M Low: $-21.36M High: $-18.96M avg. -22.18% | Avg: $-7.32M Low: $-7.83M High: $-6.95M avg. 63.30% |
EPS
% change YoY
| -$4.47 N/A | -$575.42 -12772.93% | -$2.59 99.54% | Avg: -$1.25 Low: -$2.07 High: -$0.68 avg. 51.93% | Avg: -$1.37 Low: -$2.09 High: -$0.65 avg. -10.04% | Avg: -$2.1 Low: -$2.29 High: -$1.96 avg. -53.28% | Avg: -$1.91 Low: -$2.09 High: -$1.79 avg. 9.04% |
Operating Expenses
% change YoY
| $40.79M N/A | $59.90M 46.85% | $103.65M 73.02% | Avg: $4.97M Low: $4.72M High: $5.32M avg. -95.20% | Avg: $18.79M Low: $17.86M High: $20.12M avg. 278.16% | Avg: $22.96M Low: $21.83M High: $24.59M avg. 22.18% | Avg: $8.42M Low: $8.01M High: $9.02M avg. -63.30% |
FAQ
What is Carisma Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 6.50% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -69.39M, average is -73.00M and high is -22.79M.
What is Carisma Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 46.32% in 2025-2028.
We have gathered data from 2 analysts. Their low revenue estimate is $6.84M, average is $7.19M and high is $7.70M.
What is Carisma Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -0.58% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$2.07, average is -$1.25 and high is $-0.68.
What is the best performing analyst?
In the last twelve months analysts have been covering Carisma Therapeutics stock. The most successful analyst is Justin Zelin.